Physician profile
Zohaib Haque
NPI 1023541935
$48,898.13
in general payments reported to CMS, 2019-2025
22 companies · $47K in 2025
The $47K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $368 · 2023: $892 · 2024: $603 · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $3,434 · Travel and Lodging: $1,249 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,650.00 |
| Food and Beverage | $3,434.00 |
| Travel and Lodging | $1,248.68 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,070.62 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $1,098.22 | 2023-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $605.66 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $368.28 | 2022-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $331.10 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Neurocrine Biosciences, INC. | $271.70 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $261.81 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $161.17 | 2023 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $151.71 | 2022-2023 | Austedo, Austedo Xr |
| Intra-Sana Laboratories | $124.95 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Supernus Pharmaceuticals, INC. | $94.01 | 2023-2025 | Qelbree, Qelbree |
| Acadia Pharmaceuticals INC | $69.57 | 2022-2023 | Nuplazid |
| Lundbeck LLC | $67.05 | 2022-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.22 | 2022-2023 | |
| Neos Therapeutics, LP | $34.85 | 2024 | Adzenys Xr-Odt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.86 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $21.46 | 2023 | Belsomra |
| Indivior INC. | $17.56 | 2023 | Perseris |
| Noven Therapeutics, LLC | $16.95 | 2023 | Secuado |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2025 | Cobenfy |
| Tempus Ai, INC | $14.18 | 2024 | |
| Bausch Health US, LLC | $13.53 | 2024 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zohaib Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.